Focusing on Patient Compliance

Formulation Models

Predictive Formulation: Can Modeling Reduce Empirical Development?

David Alvaro, Ph.D.

Pharma's Almanac

LNP Analytics

Beyond Particle Size: Building a Complete Analytical Strategy for LNPs

Pharma's Almanac

Nonviral Delivery

Can Nonviral Delivery Change the Economics of Gene Therapy?

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Spray-Dried Dispersions vs. Nanocrystals: Which Is Better for Solubility Enhancement?

Nice Insight

Pathfinder

Micronization vs. Nanomilling vs. Amorphous Solid Dispersions: Which Is Better for Poorly Soluble Drugs?

Nice Insight

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma

CCS and CMC

Packaging Returns to the Center of CMC Strategy

Pharma's Almanac

Child Formulation

The Pediatric Formulation Gap

Pharma's Almanac

TPDs

Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

David O’Connell

PCI Pharma Services

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics